NCT06091748View on ClinicalTrials.gov

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

PHASE3RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 22, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Interventions
DRUG

68Ga-DOTATOC

Detection of somatostatin positive lesions in GEP-NETs

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY